Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200-Day Moving Average - Here's Why

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.11 and traded as high as $5.10. Cumberland Pharmaceuticals shares last traded at $4.77, with a volume of 18,505 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, March 6th.

Cumberland Pharmaceuticals Stock Down 4.0 %

The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. The stock has a market cap of $66.63 million, a PE ratio of -6.19 and a beta of -0.24. The business has a fifty day moving average of $4.83 and a 200-day moving average of $3.11.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. The firm had revenue of $10.44 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Institutional Trading of Cumberland Pharmaceuticals

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Two Sigma Investments LP boosted its stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,649 shares of the specialty pharmaceutical company's stock after buying an additional 18,271 shares during the period. Two Sigma Investments LP owned 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent filing with the Securities & Exchange Commission. 15.51% of the stock is owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.